Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Liabilities (2023 - 2025)

Contineum Therapeutics has reported Total Liabilities over the past 3 years, most recently at $10.4 million for Q3 2025.

  • Quarterly results put Total Liabilities at $10.4 million for Q3 2025, up 78.73% from a year ago — trailing twelve months through Sep 2025 was $10.4 million (up 78.73% YoY), and the annual figure for FY2024 was $14.8 million, up 159.22%.
  • Total Liabilities for Q3 2025 was $10.4 million at Contineum Therapeutics, down from $11.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for CTNM hit a ceiling of $97.5 million in Q1 2023 and a floor of $3.9 million in Q2 2024.
  • Median Total Liabilities over the past 3 years was $11.5 million (2025), compared with a mean of $26.0 million.
  • Biggest five-year swings in Total Liabilities: tumbled 93.26% in 2024 and later soared 198.49% in 2025.
  • Contineum Therapeutics' Total Liabilities stood at $5.7 million in 2023, then soared by 159.22% to $14.8 million in 2024, then fell by 29.8% to $10.4 million in 2025.
  • The last three reported values for Total Liabilities were $10.4 million (Q3 2025), $11.5 million (Q2 2025), and $13.5 million (Q1 2025) per Business Quant data.